{
    "nctId": "NCT01286233",
    "briefTitle": "Study of Biomarkers Associated With Fatigue in Patients With Early-Stage Breast Cancer Treated With Metformin or Placebo on NCIC-CTG-MA.32",
    "officialTitle": "Biobehavioral Mechanisms of Fatigue in Patients Treated on NCIC CTG MA.32: A Phase III Randomized Trial of Metformin Versus Placebo on Recurrence and Survival in Early Stage Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer, Depression, Fatigue, Sleep Disorders",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 394,
    "primaryOutcomeMeasure": "Questionnaire scores from patient reported outcome battery regarding fatigue, stress, sleep, depression, and general quality of life",
    "eligibilityCriteria": "Inclusion Criteria\n\n* The patient must have consented to participate and must have signed and dated an appropriate IRB-approved consent form that conforms to federal and institutional guidelines for the MA.32.F Study before being enrolled.\n* The patient must be female.\n* The patient must reside in the United States or Canada.\n* The patient must be English-speaking.\n* The patient must be eligible for randomization in the MA.32 treatment trial. (Participation in the MA.32 QOL study is permitted but not required.)\n* The patient must not have started taking MA.32 study therapy.\n* The patient must have completed primary breast radiation therapy at least two weeks prior to enrollment in MA.32.F.\n\nExclusion Criteria\n\n* MA.32 study therapy has been initiated.\n* Currently receiving radiation therapy or additional radiation therapy is planned for initiation after starting MA.32 study therapy.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}